A carregar...
Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
Immune checkpoint inhibitor (ICI) therapies can achieve meaningful tumor responses in a subset of patients with most types of cancer that have been investigated. However, the majority of patients treated with these drugs do not experience any clinical benefit. Because not all patients benefit from I...
Na minha lista:
| Publicado no: | Hum Vaccin Immunother |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7012182/ https://ncbi.nlm.nih.gov/pubmed/31361563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1631136 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|